The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-25 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Following Brüning's resignation, the Centre Party entered the opposition. Though they also opposed the Nazi Party, their energies were directed mainly against the renegade Papen. Some Centre politicians were soothed by Hitler's strategy of legality into downplaying the Nazi threat. In regard to the government, the Centre Party rejected a "temporal solution", such as Papen's presidial cabinets, and rather advocated a "total solution", i.e., a government according to the rules of the constitution. Since the Centre considered Papen's administration of being "in a dangerous way dependent on radical right-wing parties", chairman Ludwig Kaas advised the President to recognise this connection by basing the government on a coalition with the rising right-wing parties, the "logical result of current development". This would force the radicals to "take their share in responsibility" and "acquainting them with international politics". The Centre would then act as the party of opposition to this administration. As Papen was faced with almost uniform opposition by the parties, he had the Reichstag dissolved. In the subsequent elections, the Centre Party campaigned on two fronts, against both the Papen government and National Socialists and reaffirmed their stance as the "constitution party" opposed to "any measure contrary to constitution, justice and law" and "unwilling to yield to terror". The July 1932 elections brought further losses to the mainstream parties and gains to the extremist parties.
=== Polymerase chain reaction === Graphene is reported to have enhanced PCR by increasing the yield of DNA product. Experiments revealed that graphene's thermal conductivity could be the main factor behind this result. Graphene yields DNA product equivalent to positive control with up to 65% reduction in PCR cycles.
=== tif-tik === tifacogin (INN) tifemoxone (INN) tifenamil (INN) tifencillin (INN) tiflamizole (INN) tiflorex (INN) tifluadom (INN) tiflucarbine (INN) tiformin (INN) tifurac (INN) tifuvirtide (INN) Tigan tigapotide (USAN) tigatuzumab (USAN) tigecycline (USAN) tigemonam (INN) tigestol (INN) tigloidine (INN) Tiject-20 Tikosyn
Sources: en.wikipedia.org
== Structure == Prohormones vary considerably in length and design, as do peptide hormones, but their base structure is the same. They consist of one or more inactive peptide hormones or hormone chains attached to each other in a way that prevents hormone expression, often by making the chains' binding ends inaccessible via folding and binding of other chains to said ends. For hormonal expression to be induced, the binding ends of hormones but either bind to receptors in the cell membrane, or in the case of steroids, bind to steroid receptor proteins in the cell, both of which mediate hormone expression.
=== Emil: The Beefy Barbarian Bully === First aired: 15 October 2009 Emil is a self-proclaimed Assyrian bully who was brought to the show by his victims, Anthony and Mo. Mo's girlfriend is friends with the bully and she feels bad because he has made their lives miserable with his bullying. Emil was pitted against emerging MMA fighter Nick Gaston, who forced him to tap out five times in one minute, thirty six seconds. He withdrew from the second round, the only contestant having done so to this point. Anthony and Mo won $10,000 and an apology from Emil.
According to Bucknell, SN 35.106 describes a non-linear "branched version" of dependent origination in which consciousness is derived from the coming together of the sense organs and the sense objects (and thus represents sense perception). The Mahānidānasutta (DN 15) describes a "looped version", in which consciousness and nama-rupa condition each other. It also describes consciousness descending into the womb. According to Bucknell, "some accounts of the looped version state explicitly that the chain of causation goes no further back than the loop. Waldron also mentions idea that in early Buddhism, consciousness may have been understood as having these two different aspects (basic consciousness or sentience and cognitive sense consciousness). While these two aspects were largely undifferentiated in early Buddhist thought, these two aspects and their relation was explicated in later Buddhist thought, giving rise to the concept of alaya-vijñana. In yet another linear version, dubbed the "Sutta-nipata version", consciousness is derived from avijja ("ignorance") and saṅkhāra ("activities" also translated as "volitional formations").
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.